Business
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology
Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advanci
About this update from Autonomix Medical, Inc.
[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics","length":204,"tagName":"p"},{"type":"text","content":"Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications ","length":126,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,257,071 (‘071 patent) titled Controlled sympathectomy and micro-ablation systems and methods. The newly issued ‘071 patent relates to, but is not necessarily limited to, advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation technologies, providing enhanced precision in treating nerve-related conditions. These systems allow for the identification and ablation of overactive nerves within the peripheral nervous system using a minimally invasive approach. The granted patent represents a significant step forward in Autonomix’s mission to improve patient outcomes by delivering more effective, less invasive treatments for neurological conditions such as chronic pain, hypertension and a myriad of other nerve-related disorders.","length":1079,"tagName":"p"},{"type":"text","content":"“We are excited to announce the issuance of this patent, marking a key milestone in our strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation. This innovative technology enhances ou...